O uso de nicotina em pacientes com esquizofrenia avaliado pelo Questionário de Tolerância de Fagerström: uma análise descritiva em uma amostra brasileira by Chaves, Leonardo & Shirakawa, Itiro
Nicotine use in patients with schizophrenia 
evaluated by the Fagerström Tolerance 
Questionnaire: a descriptive analysis from a 
Brazilian sample
O uso de nicotina em pacientes com esquizofrenia 
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Abstract
Objective: This is a descriptive study to determine smoking prevalence rates in a convenience sample of patients with schizophrenia and to 
describe clinical/demographic variables for nicotine use in this population. Method: Patients with schizophrenia were consecutively invited 
to answer a standard clinical/demographic questionnaire and a questionnaire on smoking habits (Fagerstrom Tolerance Questionnaire). 
Results: Eighty-three patients were interviewed. The smoking rate was 57.8% (n = 48). Male (68.8%) patients smoked more than 
females did (31.3%; p = 0.081). Compared to patients who smoked at the time of disease onset, those who only started smoking 
after disease onset had a lower mean age at the time of disease onset [24 years old (SD = ± 6.8) vs.19 years old (SD = ± 3.9; 
p = 0.041)]. Patients who preferred high-nicotine content cigarettes (p < 0.01) had higher frequency of smoking inhalation (p < 0.05) 
and had more urgency to smoke the first cigarette in the morning (p < 0.05). Twenty-seven (56.3%) of smoking patients were heavy 
VPRNHUV)74Conclusions: Patients with schizophrenia in our convenience sample smoked in a higher rate compared to the 
general population in Brazil. Smoking patients were heavy smokers evaluated by the Fagerstrom Tolerance Questionnaire.
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Resumo
Objetivo: Este é um estudo descritivo para determinar os índices de prevalência de tabagismo em uma amostra de conveniência de 
pacientes com esquizofrenia e para descrever variáveis clínicas/demográficas para o uso de nicotina nesta população. Método: Pa-
cientes com esquizofrenia foram convidados de forma consecutiva a responder a um questionário clínico/demográfico padrão e a um 
questionário sobre tabagismo (Questionário de Tolerância de Fagerstrom). Resultados: Oitenta e três pacientes foram entrevistados. O 
índice de tabagismo foi de 57,8% (n = 48). Pacientes masculinos (68,8%) fumaram mais do que os femininos (31,3%; p = 0,081). 
Em comparação com pacientes que fumavam no momento do início da doença, aqueles que somente começaram a fumar após o início 
da doença tiveram uma idade média de início da doença menor [24 anos de idade (DP = ± 6,8) vs.19 anos de idade (DP = ± 3,9; 
p = 0,041)]. Pacientes que preferiam cigarros com alto conteúdo de nicotina (p < 0,01) tinham freqüência mais alta de inalação de 
tabaco (p < 0,05) e tinham maior urgência pelo primeiro cigarro da manhã (p < 0,05). Vinte e sete (56,3%) dos pacientes fumantes 
HUDPIXPDGRUHVSHVDGRV)74Conclusões: Os pacientes com esquizofrenia em nossa amostra de conveniência tiveram índices 
mais elevados de tabagismo em comparação com a população geral do Brasil. Pacientes tabagistas eram tabagistas pesados segundo 
a avaliação do Questionário de Tolerância de Fagerstrom.
Descritores: Nicotina; Tabagismo; Esquizofrenia; Análise estatística; Apresentação de dados
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Introduction
Nicotine dependence is the most common comorbidity among 
patients with schizophrenia, occurring in 50 to 90% of the patients.1
Many factors should be considered in the management of these 
patients including nicotine stimulating effects in neurotransmission, 
reduction of circulating levels of antipsychotic medications; 
improvement in cognitive functioning, and withdrawal symptoms 
that could worsen in psychiatry symptoms. 
Previously published reports indicate that first-episode 
schizophrenia patients smoke in the same intensity as those 
who are chronic patients.2 Adler et al. suggested that cognitive 
deficits could be responsible for nicotine intake among patients 
with schizophrenia.3 Patients would self-medicate with nicotine to 
alleviate both positive and negative symptoms.4
Chronic nicot ine use could increase dopaminergic 
neurotransmission, especially in the prefrontal cortex.5 Reducing 
prefrontal activity could lead to negative symptoms and cognitive 
deficits;6 therefore, improvement in dopaminergic activity in this 
region by nicotine could alleviate these symptoms. The resulting 
symptom relief could motivate patients with schizophrenia to 
continue smoking. 
Morphological examinations found alterations in nicotinic 
receptors in postmortem tissue of individuals with schizophrenia 
compared to controls, especially in the A-7 and A-4b2 subtypes. In 
nicotinic receptor stimulation studies of patients with schizophrenia, 
improvement in sensory inhibition and cognitive deficits were 
observed following treatment, although the effects were transient.7
Alfa -7-type nAChRs have been suggested to be potential therapeutic 
targets for Alzheimer’s disease, schizophrenia and possibly other 
pathologies. Acetylcholine receptors containing alfa-6 subunits 
have been suggested to have a role in nicotine-evoked dopamine 
release.8 In our study we investigated the smoking prevalence and 
smoking habits among patients with schizophrenia.
Method
Eighty-three patients were interviewed from April to May of the 
year 2002 in two psychiatry care units. None of the patients we 
approached declined participation in the interview. Inclusion criteria 
comprised aging from 18 to 65 years and meeting CID-10 criteria for 
schizophrenia (F20 to F25). The exclusion criterion was inability to 
answer the interview due to disorganized speech or thought content. 
The study was reviewed and approved by the Ethics Committee 
Board at Hospital São Paulo under the number – CEP 0353/02.
All patients answered a standard clinical/demographic 
questionnaire. Smoking patients responded to the Fagerström 
Tolerance Questionnaire (FTQ). FTQ evaluates smoking dependence 
from zero to eleven points (mild = zero to 4; moderate = 6 and 
7; severe = 8 to 11). 
An Ethics Committee Board (ECB) approved the study. Patients 
were included in the study after signing the approved informed 
consent form. 
Clinical and demographic variables were evaluated using the chi-
square test. Smoking dependence was determined through the FTQ. 
FTQ total score distribution was evaluated by clinical and demographic 
categorized variables using the t-student test for age in years of treatment 
onset, and chi-square test for all other variables.
Results
The overall rate of smoking was 57.8%. Forty-eight (57.8%) 
were males and 35 (42.2%) were females. Male (68.8%) patients 
smoked more than female patients (31.3%; p = 0.081). Among 
smokers, those who already smoked at the time of disease onset 
had a mean age at disease onset of 24 years old (SD = ± 6.8). 
Those who only started smoking after schizophrenia onset had 
an earlier disease onset, around 19 years old (SD = ± 3.9). This 
comparison was statistically significant (p = 0.041).
Twenty-seven (56.3%) of the patients who were smokers were 
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differences in 3 of the 8 variables: high-nicotine content cigarettes 
(p < 0.01), smoking inhalation frequency (p < 0.05) and urgency 
for the first cigarette in the morning (p < 0.05). 
Discussion
The rate of 57.8% we found in our convenience sample was 
similar to studies that assessed samples of younger patients but 
with a higher frequency of males.9 To our knowledge, this is the 
first Brazilian study to describe factors associated with nicotine use 
in schizophrenia.
Kelly et al. found a rate of 58% of nicotine consumption 
prevalence.4 Male patients (68.8%) smoked more than female 
did (31.3%; p = 0.018). Compared to patients who smoked 
at the time of disease onset, those who only started smoking 
after the disease onset had a lower mean age at the  onset of 
schizophrenia [24 years old (SD = ± 6.8) vs.19 years old 
(SD = ± 3.9; p = 0.041)]. Kelly et al. observed that individuals 
with schizophrenia started to smoke at least 4 years earlier 
before disease onset, but this difference was not statistically 
significant.4
Freedman et al. suggested that vulnerability to schizophrenia 
was associated with smoking.10 Patients with schizophrenia would 
have more difficulty in discriminating stimuli, a deficit also found 
in family members. Nicotine use would normalize these deficits 
through stimulation of specific receptors with low affinity to nicotine, 
therefore family members who are not affected by schizophrenia 
would smoke more than the non-affected general population.
Freedman et al. suggested variations in the regulation of A-7
nicotinergic gene subunits in chromosome 15 could be a marker 
of schizophrenia.11 Adler et al. observed a brief and temporary 
normalization of P50 wave in evoked potential when nicotine was 
administered acutely in schizophrenic family members and in 
patients.12 They conclude this brief normalization could improve 
cognitive symptoms, making patients would seek for nicotine by 
brain reward and reinforcement mechanisms. 
The FTQ scores showed statistically significant differences in 3 
individual items of the FTQ: nicotine content cigarettes (high-nicotine 
cigarette content), frequency of smoking inhalation (always inhale 
smoke) and urgency to smoke (smoke up to 30 minutes) - Table 
1. These patients prefer high-nicotine content cigarettes and most 
frequently smoke the cigarette until the very end where nicotine 
concentration is higher.13
It seems that studies investigating neurobiological relations 
between smoking and schizophrenia provide us with more robust 
evidence that could be replicated in similar studies.
The main limitation of our study is the sample size. However, it 
points that nicotine use is high among patients with schizophrenia. 
It raises the discussion whether smoking could be a marker for the 
neurodevelopmental form of the illness or it could play a protective 
role in vulnerable individuals with schizophrenia. Larger comparative 
studies are warranted in determining nicotine’s role in our population 
with schizophrenia.
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